S
Sven Mahner
Researcher at Ludwig Maximilian University of Munich
Publications - 545
Citations - 12728
Sven Mahner is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Ovarian cancer & Medicine. The author has an hindex of 46, co-authored 439 publications receiving 9126 citations. Previous affiliations of Sven Mahner include Charité & University of Hamburg.
Papers
More filters
Journal ArticleDOI
561P When to treat the pelvis in node-positive vulvar cancer: Results from the AGO-VOP.2 QS vulva study
Monika Hampl,Andrew Jaeger,CZ Eulenburg,Katharina Prieske,J. Hambrecht,Sophie Fuerst,R Klapdor,Sabine Heublein,Paul Gass,Alison Rohner,Ulrich Canzler,S. Becker,Mareike Bommert,Dirk Bauerschlag,Agnieszka Denecke,LC Hanker,Jalid Sehouli,Christian Dannecker,Sven Mahner,Linn Woelber +19 more
TL;DR: In this paper , 306 patients with primary node-positive vulvar squamous cell carcinoma (VSCC) after surgical groin staging treated at 33 gynecologic oncology centers in Germany between 2017-2019 were analyzed with regard to pelvic treatment, risk for pelvic nodal involvement and prognosis.
Journal ArticleDOI
Ovarialkarzinom: Neoadjuvante Chemotherapie versus primäre zytoreduktive Operation
TL;DR: Wie hat sich der Umgang mit neoadjuvanter Chemotherapie bei Patientinnen mit fortgeschrittenem Ovarialkarzinom entwickelt, seit Studiendaten dafür sprachen, dass sie der primären zytoreduktiven Operation nicht unterlegen ist?
Journal ArticleDOI
Use of Granulocyte-colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells-Results From the SUCCESS A Trial.
Philip Hepp,Peter A. Fasching,Matthias W. Beckmann,Tanja Fehm,J. Salmen,Carsten Hagenbeck,Bernadette Jäger,Peter Widschwendter,Nikolaus de Gregorio,Fabienne Schochter,Sven Mahner,Nadia Harbeck,Tobias Weissenbacher,Ayse-Gül Kurt,Thomas W. P. Friedl,Wolfgang Janni,Brigitte Rack +16 more
TL;DR: Cautious interpretation is needed regarding elevated levels of MUC‐1–derived tumor markers such as CA27.29 shortly after adjuvant chemotherapy when G‐ CSF has been given, because G‐CSF treatment was associated with increased CA 27.29 levels after chemotherapy.
Journal ArticleDOI
Treatment and outcome of patients with high-grade advanced ovarian cancer (AOC): Real-world data in Germany (QS Ovar of the AGO Study Group).
Sven Mahner,Philipp Harter,Andreas du Bois,Felix Hilpert,M Kerkmann,Jalid Sehouli,Nikolaus de Gregorio,Lars Hanker,Florian Heitz,Frederik Marmé,Linn Woelber,Laura Holtmann,G. Elser,Jacobus Pfisterer +13 more
TL;DR: Patient outcome regarding PFS and OS was best when complete tumor resection was achieved at primary surgery and patients received combination chemotherapy with maintenance treatment, based on a representative cohort of patients with advanced ovarian cancer in Germany.